Despite weight loss and glycemic control, experts caution that type 2 diabetes remission is not a cure and that pancreatic ...

A team of researchers from Cleveland Clinic Genomic Medicine share insights from an early set of 19,000 patients to receive immune checkpoint inhibitor treatments for colorectal cancer in the U.S.

The use of an automated insulin delivery (AID) system reduced A1c and hyperglycemia without increasing hypoglycemia in people ...

SGLT2 inhibitor use was not associated with an increased risk for postoperative diabetic ketoacidosis among patients with type 2 diabetes.

Adults with overweight or obesity and type 2 diabetes who are given the sodium glucose cotransporter 2 (SGLT-2) inhibitor drug dapagliflozin alongside moderate calorie restriction achieve much higher ...

Compared with vs DPP4 inhibitors, SGLT2 inhibitors reduce the risk for kidney and ureteral stones in patients with type 2 diabetes, including those with a stone history. Sodium-glucose cotransporter 2 ...

BACKGROUND: Despite the high morbidity and mortality of heart failure with preserved ejection fraction (HFpEF), treatment ...

SGLT2 inhibitors were associated with better cardioprotective effects among older adults than younger adults with type 2 diabetes.

The safety profile of ICP-488 was similar to placebo. ORLANDO — A once-daily, oral tyrosine kinase 2 inhibitor was safe and “highly effective” in adults with moderate to severe plaque ...

The cardiorenal benefits of SGLT2 inhibitors (SGLT2-i) in DKD patients have been demonstrated through numerous large clinical trials. Moreover, further exploratory experiments indicate these drugs may ...

New phase 3b trial results show Lilly’s Trulicity has helped type 2 diabetes patients already taking an SGLT2 inhibitor but whose blood sugar was inadequately controlled. The AWARD trial showed ...

After adjustment for confounding variables, no increased risk seen for GLP-1 receptor agonists versus DPP-4 inhibitors, SGLT-2 inhibitors. HealthDay News — Glucagon-like peptide-1 (GLP-1) receptor ...